Alxn stock price target

On average, they anticipate Alexion Pharmaceuticals' stock price to reach $148.20 in the next year. This suggests a possible upside of 64.9% from the stock's current price. View analysts' price targets for Alexion Pharmaceuticals .

ALXN Stock Price, Forecast & News (Alexion Pharmaceuticals) On average, they anticipate Alexion Pharmaceuticals' stock price to reach $148.20 in the next year. This suggests a possible upside of 64.9% from the stock's current price. View analysts' price targets for Alexion Pharmaceuticals . Alexion Pharmaceuticals, Inc. ALXN price target raised to ... Apr 26, 2019 · The current consensus rating on Alexion Pharmaceuticals, Inc. ALXN, -1.41% is Buy with a consensus target price of $164.1333 per share, a potential 23.03% upside.

ALXN Stock Price, Forecast & News (Alexion Pharmaceuticals)

Alexion Pharmaceuticals Inc. Research & Ratings (ALXN ... Apr 03, 2020 · View today's stock price, news and analysis for Alexion Pharmaceuticals Inc. (ALXN). Barron's also provides information on historical stock ratings, target prices, company earnings, market Alexion Pharmaceuticals (NASDAQ:ALXN) Price Target Raised ... Alexion Pharmaceuticals (NASDAQ:ALXN) had its target price boosted by SunTrust Banks from $20.00 to $141.00 in a research note issued to investors on Friday, The Fly reports. The firm presently Alexion Pharmaceuticals (ALXN) Stock Price Target Lowered ... Feb 01, 2016 · NEW YORK -- Credit Suisse lowered its price target on Alexion Pharmaceuticals () - Get Report to $195 from $201 and maintained its "neutral" rating on the stock …

Nov 09, 2019 · Their average twelve-month price target is $160.56, suggesting that the stock has a possible upside of 63.16%. The high price target for ALXN is $186.00 and the low price target for ALXN is $135.00. There are currently 3 hold ratings and 15 buy ratings for the stock, resulting in a …

Alexion Pharmaceuticals (NasdaqGS:ALXN) - Share price ... Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and … ALEXION PHARMACEUTICALS : ALXN Stock Price | MarketScreener Alexion Pharmaceuticals, Inc. specializes in the research and development of therapeutic products used in treating hematological and cardiovascular diseases, auto-immune diseases, and cancers. ALXN -- Is Its Stock Price A Worthy Investment? Learn More.

Feb 27, 2020 The forecasts give the Alexion Pharmaceuticals Inc. stock a consensus price target representing an upside potential 33.55. Earnings Forecast.

Feb 21, 2019 · With that in mind, he suggests a 34% upside to the stock, and price target of $175. Alexion is another strong buy , with eight "buy" ratings and one "hold." The stock's $129 share price and $165 Alexion Pharmaceuticals (NasdaqGS:ALXN) - Share price ...

Explore commentary on Alexion Pharmaceuticals Inc. and hear what the experts at TheStreet are saying about ALXN. Subscribe; Log In case to buy the stock. price target lowered to $133 from

Alexion Pharmaceuticals, Inc. specializes in the research and development of therapeutic products used in treating hematological and cardiovascular diseases, auto-immune diseases, and cancers. At the end of 2019, the group had a portfolio of 6 products in clinical development. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) price target ... Apr 26, 2019 · Today, Raymond James raised its price target on Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to $164.00 per share. There are 12 Buy Ratings, 3 … ALXN Alexion Pharmaceuticals, Inc. — Stock Price and ...

Is Alexion Pharmaceuticals, Inc. (ALXN) a Keeper? Bullish ... SunTrust gave “Buy” rating to ALXN stocks, setting the target price at $125 in the report published on November 12, 2019. ALXN Stocks -5.50% Far from 50 Day Moving Average After a stumble in the market that brought ALXN to its low price for the period of the last 52 weeks, Alexion Pharmaceuticals, Inc. was unable to take a rebound, for now settling with -26.94% of loss for the given period. ALEXION PHARMACEUTICALS : ALXN Stock Price | MarketScreener Alexion Pharmaceuticals, Inc. specializes in the research and development of therapeutic products used in treating hematological and cardiovascular diseases, auto-immune diseases, and cancers. At the end of 2019, the group had a portfolio of 6 products in clinical development.